Extraordinary innovations have led to the introduction of highly effective cancer treatments. These treatments include surgery, radiotherapy, chemotherapy, hormonal therapy, haematopoietic stem cell transplant, and, more recently, immunotherapy. Unfortunately, these remarkable treatments, and resultant improved rates of survival, can be accompanied by significant complications, including chronic pain. The prevalence of pain in the population of cancer survivors is estimated to be greater than 40%, with significant associated impairment of quality of life. It is important to note that cancer survivors may have received more than one of these therapies, considerably increasing the risk of developing chronic pain. The management of pain in cancer survivors requires thorough assessment of pain, function, and risk factors for misuse of opioids or other substances. Awareness of the types of cancer pain syndromes that may occur, along with treatment options, is crucial. Multimodal interventions should be incorporated into the plan of care, including pharmacological, non-pharmacological, cognitive behavioural, interventional, and integrative therapies. Despite the high exposure to these cancer therapies, and the significant prevalence of chronic pain that can occur, little research has been conducted to elucidate the resultant painful syndromes caused by these treatments clearly, much less develop effective management strategies for these disorders. Recent guidelines advance key treatment principles in this evolving population.